OTC Pharmaceuticals

A combination of unique cannabinoids & terpenes formulations for the treatment of palliative, inflammation-related and other cure-deficient conditions 

Based on real Israeli and US patients evidence, we have targeted several medical conditions that lack true remedies in the conventional medical world.

Inflammatory diseases include a vast array of disorders and conditions that are characterized and caused by inflammation. Examples include allergy, asthma, rheumatoid arthritis, psoriasis, celiac disease, multiple sclerosis, lupus, hepatitis, inflammatory bowel disease (IBD), diabetes mellitus type 1, pain and transplant rejection.

 

Sadé is one of the founding investors in PlantEXT.  The collaboration helps develop cannabis designed to help relieve the symptoms of inflammation-related conditions. Rather than simply providing cannabis oil as a treatment, Sadé promotes the creation of unique, patent-pending formulas that employ effective delivery systems targeted to improve outcomes for specific, inflammation-related conditions. This is done through the expansion of clinical studies, development of IP and products for pain - and more.

 

With a world-class team and lab facilities, Sadé  is driving rapid cannabis product development and commercialization for selected indications relief. Our first products are expected to reach the markets in 2019.

Sapir 8. St.
Nes Ziona

Israel

contact@sade.group

© 2018 by Sade Group